Section Arrow
Quote
PLX.NYSE-M
- Protalix BioTherapeutics
Quotes are at least 15-min delayed:2026/04/22 00:06 EDT
Regular Hours
Last
 2.22
-0.05 (-2.20%)
Day High 
2.29 
Prev. Close
2.27 
1-M High
2.385 
Volume 
533.92K 
Bid
2.22
Ask
2.3
Day Low
2.21 
Open
2.29 
1-M Low
2.03 
Market Cap 
182.90M 
Currency 美元 
P/E 26.63 
%Yield -- 
10-SMA 2.29 
20-SMA 2.22 
50-SMA 2.59 
52-W High 3.19 
52-W Low 1.32 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.08/0.07
Enterprise Value
189.83M
Balance Sheet
Book Value Per Share
0.60
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
52.74M
Operating Revenue Per Share
0.79
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
GERNGeron Corp1.5-0.06-3.85%-- 
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.